Bivalent Bio presents preclinical data for BVB-101 at AACR Annual Meeting
New data highlight dose-dependent tumour regression and a favourable selectivity profile for the lead bispecific programme.
Read more →Clinical-stage bispecific antibodies
Engineering bispecific antibodies for the next generation of targeted therapies.
Bivalent Bio is a clinical-stage biotechnology company developing bispecific antibodies that engage two biological targets simultaneously, unlocking precision and potency beyond conventional monoclonals.
Our focus
Bridging the limits of single-target therapeutics
We design bispecific antibodies that bridge the limits of single-target therapeutics. By engaging two epitopes in parallel, our molecules can localise activity, redirect immune cells, and overcome the resistance mechanisms that limit traditional approaches. Our lead programme is advancing toward IND filing in the second half of 2026.
Pipeline
A focused portfolio, advancing toward the clinic
Programme
Modality
Indication
BVB-101Lead programme
ModalityBispecific IgG
IndicationUndisclosed solid tumour
IND-enabling
Why bispecifics
Two targets. One engineered molecule.
Dual engagement
Simultaneous binding of two targets enables conditional activity and improved selectivity.
Tunable design
Format selection, valency, and geometry are engineered to match each biological problem.
Therapeutic reach
Applicable across oncology, autoimmunity, and inflammation where monospecifics fall short.
Latest news
What's new at Bivalent Bio
Bivalent Bio appoints Vice President of CMC as IND-enabling activities accelerate
The appointment strengthens process development and GMP manufacturing leadership ahead of first IND filing.
Read more →Bivalent Bio closes seed extension to advance lead bispecific programme
Proceeds will fund IND-enabling studies for BVB-101 and continued discovery across the bispecific portfolio.
Read more →Let's build the next bispecific together
Interested in development or manufacturing partnerships? We'd welcome a conversation.